WACKER expands production capacity for biopharmaceuticals in San Diego
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
FDA has concluded that this inspection is 'closed'
The company will respond to the Warning Letter within the stipulated timelines
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
A five-day inspection was concluded successfully with no critical and no major observations raised
Additional capacity broadens Grace’s fine chemical capabilities for API production
Subscribe To Our Newsletter & Stay Updated